In contrast, CS1 (also known as SLAMF7 or CD319) is highly expressed on multiple types of MM and has been found on 90–97% of patient MM samples17,18, and an anti-CS1 CAR-T-cell therapy19 is currently being tested in the clinic (NCT03710421). This evidence concerns the gene SLAMF7 and Miyoshi myopathy.